Abstract
Cancer therapy has evolved from surgery and radiation to multi-agent chemotherapy, and although we have seen decreased mortality and increased cure rates, most of this therapy has continued to focus on the tumor itself, and not on the tumor microenvironment. Various cells within the tumor microenvironment have been implicated in leading to resistance to immune therapy. Through a complex system of steps, T-cells become activated after presentation of a specific antigen. Because continuous T-cell activation can lead to lymphoproliferation and unwanted autoimmunity, the human T-cell immune system has evolved into a process of checks-and-balances, referred to as immune checkpoints, that allows for co-inhibitory receptors to inhibit T-cell activation. Through the use of check point inhibitors, we have seen patients with cancers refractory to multiple treatments have durable responses, and in some, long term remissions. Some of the most studied inhibitors include Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4), although more have been identified. As we continue to explore possible treatment options for cancer, we must also be diligent in preemptively investigating how and why some patients will become resistant to these treatments, and what, if any, actions can be taken to circumvent this resistance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- APC:
-
Antigen Presenting Cells
- ASCT:
-
Autologous Stem Cell Transplant
- BV:
-
Brentuximab Vedotin
- CAF:
-
Cancer Associated Fibroblasts
- COG:
-
Children’s Oncology Group
- CTLA-4:
-
Cytotoxic T-Lymphocyte Associated Antigen-4
- FDA:
-
Food and Drug Administration
- HL:
-
Hodgkin Lymphoma
- HSC:
-
Hematopoietic Stem Cells
- ICAM:
-
Intracellular Activation Motifs
- ICOS+:
-
Inducible Costimulatory
- IDO:
-
Indoleamine 2, 3-Droxygenase
- ITAM:
-
Immunoreceptor Tyrosine Based Activation Motifs
- LAG-3:
-
Lymphocyte Activation Gene 3
- MDSC:
-
Myeloid Derived Suppressor Cells
- MHC:
-
Major Histocompatibility Complex
- MHC I:
-
Major Histocompatibility Complex Class I
- MHC II:
-
Major Histocompatibility Complex Class II
- NSCLC:
-
Non-small Cell Lung Cancer
- ORR:
-
Objective Response Rate
- OS:
-
Overall Survival
- PD-1:
-
Programmed Cell Death Protein 1
- PD-L1:
-
Programmed Cell Death Ligand 1
- PD-L2:
-
Programmed Cell Death Ligand 2
- PFS:
-
Progressive Free Survival
- R/R:
-
Relapsed/Refractory
- TAM:
-
Tumor Associated Macrophages
- TCR:
-
T-Cell Receptors
- TIM-3:
-
T-cell Immunoglobulin Mucin 3
- Treg:
-
Regulatory T-cells
References
Yuan Y, Jiang YC, Sun CK, Chen QM. Role of the tumor microenvironment in tumor progression and the clinical applications (review). Oncol Rep. 2016;35(5):2499–515.
Wang Q, Wu X. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. Int Immunopharmacol. 2017;46:210–9.
Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74–80.
Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368(1):7–13.
Vardhana S, Younes A. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica. 2016;101(7):794–802.
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–23.
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61.
Orkin SH, Nathan DG. Nathan and Oski’s hematology of infancy and childhood, vol. xxvi. 7th ed. Philadelphia: Saunders/Elsevier; 2009. p. 1841.
Rothenberg EV, Taghon T. Molecular genetics of T cell development. Annu Rev Immunol. 2005;23:601–49.
Grossi CE, Favre A, Giunta M, Corte G. T cell differentiation in the thymus. Cytotechnology. 1991;5(Suppl 1):113–6.
Viret C, Janeway CA Jr. MHC and T cell development. Rev Immunogenet. 1999;1(1):91–104.
Veillette A, Bookman MA, Horak EM, Bolen JB. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell. 1988;55(2):301–8.
Nel AE. T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J Allergy Clin Immun. 2002;109(5):758–70.
Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007;7(11):880–7.
Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25–39.
Hude I, Sasse S, Engert A, Brockelmann PJ. The emerging role of immune checkpoint inhibition in malignant lymphoma. Haematologica. 2017;102(1):30–42.
Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily—CTLA-4. Nature. 1987;328(6127):267–70.
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.
Auchincloss H, Turka LA. CTLA-4: not all costimulation is stimulatory. J Immunol. 2011;187(7):3457–8.
Menter T, Tzankov A. Mechanisms of immune evasion and immune modulation by lymphoma cells. Front Oncol. 2018;8:54.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015;33(10):1191–6.
Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517–9.
Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.
Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581–8.
Diefenbach CS, Hong FX, Cohen JB, Robertson MJ, Ambinder RF, Fenske TS, et al. Preliminary safety and efficacy of the combination of Brentuximab Vedotin and Ipilimumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer research group (E4412). Blood. 2015;126:23.
Oiseth SJ, Aziz Mohamed S. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat. 2017;3:250–61.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32.
Ribas A, Wolchok JD, Robert C, Kefford R, Hamid O, Daud A, et al. Updated clinical efficacy of the anti-Pd-1 monoclonal antibody Pembrolizumab (Mk-3475) in 411 patients with Melanoma. Eur J Cancer. 2015;51:E24–E.
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18.
Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–62.
Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203–20.
Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death-1 blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure. J Clin Oncol. 2016;34(31):3733–9.
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–42.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9.
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–39.
ClinicalTrials.gov. Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation) [cited 2018 October 7, 2016]. Available from: https://clinicaltrials.gov/ct2/show/NCT02927769.
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. New Engl J Med. 2017;377(14):1345–56.
Michot JM, Lazarovici J, Ghez D, Danu A, Ferme C, Bigorgne A, et al. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. Eur J Cancer. 2017;85:67–77.
Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690–7.
Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58–67.
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.
Heigener DF, Reck M. Advanced non-small cell lung cancer: the role of PD-L1 inhibitors. J Thorac Dis. 2018;10(Suppl 13):S1468–S73.
Shirley M. Avelumab: a review in metastatic Merkel cell carcinoma. Target Oncol. 2018;13(3):409–16.
O’Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81.
O’Donnell JS, Smyth MJ, Teng MW. Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade? Genome Med. 2016;8(1):111.
Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–29.
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.
Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139–45.
Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;29(3):285–96.
Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170(6):1120–33 e17.
Bai J, Gao Z, Li X, Dong L, Han W, Nie J. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget. 2017;8(66):110693–707.
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9–16.
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.
Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of Neoantigen landscape during immune checkpoint blockade in non-small cell lung Cancer. Cancer Discov. 2017;7(3):264–76.
Li L, Dong M, Wang XG. The implication and significance of Beta 2 microglobulin: a conservative multifunctional regulator. Chin Med J. 2016;129(4):448–55.
Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, et al. Classical Hodgkin lymphoma with reduced beta2M/MHC class I expression is associated with inferior outcome independent of 9p24.1 status. Cancer Immunol Res. 2016;4(11):910–6.
Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA. 2013;110(27):11091–6.
Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, et al. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res. 2015;3(5):506–17.
Ribas A. Releasing the brakes on Cancer immunotherapy. N Engl J Med. 2015;373(16):1490–2.
Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39.
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.
Acknowledgement
This work was supported in part from the Pediatric Cancer Research Foundation and St. Baldrick’s Foundation. The authors would like to thank Virginia Davenport, RN and Erin Morris, RN in their assistance in the preparation of this manuscript.
Disclosure of Conflict of Interest
No potential conflicts of interest were disclosed.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Audino, A.N., Cairo, M.S. (2019). Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs. In: Xavier, A., Cairo, M. (eds) Resistance to Targeted Therapies in Lymphomas . Resistance to Targeted Anti-Cancer Therapeutics, vol 21. Springer, Cham. https://doi.org/10.1007/978-3-030-24424-8_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-24424-8_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-24423-1
Online ISBN: 978-3-030-24424-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)